NR 547 PRACTICE EXAM PACKAGE DEAL | 2026/2027
Edition | 200 Verified Questions - 148 Questions with Answers
NR 547 Advanced Pharmacology Midterm Exam 2026-148 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice exam package for NR 547 (Advanced Pharmacology) provides 200
verified questions designed to assess and reinforce mastery of pharmacotherapeutic principles. The
questions reflect the latest evidence-based guidelines and are structured to mirror the rigor of the actual
midterm examination. Each question is accompanied by a detailed rationale, ensuring a deep
understanding of drug mechanisms, interactions, and clinical applications. This resource is essential for
nursing students seeking to excel in their pharmacology coursework and achieve a top grade.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Prescribing for special populations (pediatric, geriatric, pregnancy)
Adverse effects, drug interactions, and contraindications
Clinical decision-making and patient education
Case-based scenarios and prioritization
Updates for 2026:
- Updated to reflect the latest 2026-2027 clinical practice guidelines
- Incorporated new FDA-approved medications and revised safety warnings
- Enhanced rationales with evidence-based references
- Added more case-based questions to improve critical thinking
- Aligned with current NR 547 course objectives and exam blueprint
Abstract:
The NR 547 Practice Exam Package Deal is a meticulously curated collection of 200 exam-style questions tailored
for advanced pharmacology students. This edition has been updated to align with the 2026-2027 academic year,
ensuring relevance and accuracy. The questions span a wide range of topics, including pharmacokinetics,
pharmacodynamics, drug classifications, and therapeutic applications. Each question is designed to challenge the
student's understanding and application of pharmacological principles in clinical scenarios. Detailed rationales
are provided for both correct and incorrect answers, facilitating a comprehensive learning experience. The
package also includes a breakdown of content areas and their respective weights, allowing students to focus their
study efforts effectively. With a focus on evidence-based practice and patient safety, this resource is an invaluable
tool for exam preparation and clinical competence.
Keywords:
NR 547, Advanced Pharmacology, Practice Exam, Pharmacotherapeutics, Drug Interactions, Nursing Education,
Exam Prep, 2026-2027
Answer Format:
Each question is followed by four answer choices, with the correct answer clearly indicated. A detailed rationale
explains why the correct answer is right and why the distractors are incorrect, referencing current guidelines and
pharmacological principles. This format reinforces learning and helps students identify common misconceptions.
Compliance Checklist:
Aligned with NR 547 course objectives
Based on latest 2026-2027 clinical guidelines
Page 1
, Includes rationales for all answers
Verified for accuracy by subject matter experts
Suitable for self-assessment and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, Distribution, Metabolism, 20%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Drug Classifications and 41-80 Antibiotics, Cardiovascular Agents, CNS 20%
Mechanisms Drugs, Endocrine Agents, Analgesics
Special Populations 81-110 Pediatrics, Geriatrics, Pregnancy/Lactation, 15%
Renal/Hepatic Impairment
Adverse Effects and Interactions 111-140 Side Effects, Drug-Drug Interactions, 15%
Contraindications, Toxicity Management
Clinical Decision-Making 141-170 Prescribing, Monitoring, Patient Education, 15%
Evidence-Based Practice
Case-Based Scenarios 171-200 Integrated Cases, Prioritization, Critical 15%
Thinking, Application
Page 2
,Q1. A patient with chronic kidney disease (eGFR 25 mL/min) and type 2 diabetes is
prescribed metformin. Which pharmacokinetic principle most directly explains the
increased risk of lactic acidosis in this patient?
A. Decreased first-pass metabolism leading to higher bioavailability
B. Reduced renal clearance causing drug accumulation
C. Increased volume of distribution due to edema
D. Altered protein binding increasing free drug fraction
Correct Answer: B. Reduced renal clearance causing drug accumulation
Rationale: Metformin is primarily excreted unchanged by the kidneys. In chronic kidney
disease, reduced renal clearance leads to drug accumulation, increasing the risk of lactic
acidosis. The other options are less directly related to metformin's pharmacokinetic
profile.
Why Wrong:
A - Metformin undergoes minimal first-pass metabolism; this is not the primary
mechanism.
C - Volume of distribution changes are not the main cause of metformin-induced lactic
acidosis in renal impairment.
D - Metformin is not highly protein-bound; altered protein binding is not a significant
factor.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 47
Q2. A patient on warfarin is started on rifampin for tuberculosis. Which
pharmacodynamic interaction is expected, and what monitoring adjustment is
required?
A. Increased warfarin effect; reduce warfarin dose
B. Decreased warfarin effect; increase warfarin dose
C. No interaction; monitor INR routinely
D. Increased bleeding risk; hold warfarin
Correct Answer: B. Decreased warfarin effect; increase warfarin dose
Rationale: Rifampin is a potent CYP450 enzyme inducer, particularly CYP2C9, which
metabolizes warfarin. This increases warfarin metabolism, decreasing its anticoagulant
effect, so the warfarin dose must be increased to maintain therapeutic INR.
Why Wrong:
A - Rifampin induces metabolism, not inhibits, so warfarin effect is decreased, not
increased.
C - A significant interaction exists; INR must be monitored more frequently and dose
adjusted.
D - Bleeding risk is decreased, not increased, due to reduced warfarin activity.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q3. A patient with major depressive disorder is prescribed phenelzine. Which dietary
restriction is critical to prevent a hypertensive crisis, and what is the mechanism?
A. Avoid tyramine-rich foods; MAO-A inhibition prevents tyramine metabolism
B. Avoid foods high in potassium; MAO-A inhibition alters electrolyte balance
C. Avoid caffeine; MAO-A inhibition potentiates stimulant effects
D. Avoid foods high in sodium; MAO-A inhibition causes fluid retention
Correct Answer: A. Avoid tyramine-rich foods; MAO-A inhibition prevents tyramine
metabolism
Rationale: Phenelzine is a nonselective MAO inhibitor. It blocks MAO-A in the gut,
preventing the breakdown of tyramine, leading to accumulation and release of
norepinephrine, causing hypertensive crisis. Tyramine-rich foods (aged cheese, cured
meats) must be avoided.
Why Wrong:
B - Potassium is not directly affected by MAO inhibition; this is not a dietary
restriction.
C - Caffeine is not specifically restricted with MAO inhibitors; tyramine is the main
concern.
D - Sodium restriction is not required; the interaction is with tyramine, not sodium.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29
Q4. Which drug is most likely to cause QT prolongation, and what electrolyte
imbalance exacerbates this risk?
A. Amiodarone; hypokalemia
B. Metformin; hyperkalemia
C. Lisinopril; hypocalcemia
D. Atorvastatin; hypermagnesemia
Correct Answer: A. Amiodarone; hypokalemia
Rationale: Amiodarone is a class III antiarrhythmic known to prolong the QT interval.
Hypokalemia (and hypomagnesemia) increases the risk of torsades de pointes by altering
cardiac repolarization. The other drugs are not associated with QT prolongation.
Why Wrong:
B - Metformin does not prolong QT and hyperkalemia is not an exacerbating factor.
C - Lisinopril does not prolong QT; hypocalcemia is not the primary electrolyte
concern.
D - Atorvastatin does not prolong QT; hypermagnesemia is not a risk factor.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 50
Page 4
Edition | 200 Verified Questions - 148 Questions with Answers
NR 547 Advanced Pharmacology Midterm Exam 2026-148 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice exam package for NR 547 (Advanced Pharmacology) provides 200
verified questions designed to assess and reinforce mastery of pharmacotherapeutic principles. The
questions reflect the latest evidence-based guidelines and are structured to mirror the rigor of the actual
midterm examination. Each question is accompanied by a detailed rationale, ensuring a deep
understanding of drug mechanisms, interactions, and clinical applications. This resource is essential for
nursing students seeking to excel in their pharmacology coursework and achieve a top grade.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Prescribing for special populations (pediatric, geriatric, pregnancy)
Adverse effects, drug interactions, and contraindications
Clinical decision-making and patient education
Case-based scenarios and prioritization
Updates for 2026:
- Updated to reflect the latest 2026-2027 clinical practice guidelines
- Incorporated new FDA-approved medications and revised safety warnings
- Enhanced rationales with evidence-based references
- Added more case-based questions to improve critical thinking
- Aligned with current NR 547 course objectives and exam blueprint
Abstract:
The NR 547 Practice Exam Package Deal is a meticulously curated collection of 200 exam-style questions tailored
for advanced pharmacology students. This edition has been updated to align with the 2026-2027 academic year,
ensuring relevance and accuracy. The questions span a wide range of topics, including pharmacokinetics,
pharmacodynamics, drug classifications, and therapeutic applications. Each question is designed to challenge the
student's understanding and application of pharmacological principles in clinical scenarios. Detailed rationales
are provided for both correct and incorrect answers, facilitating a comprehensive learning experience. The
package also includes a breakdown of content areas and their respective weights, allowing students to focus their
study efforts effectively. With a focus on evidence-based practice and patient safety, this resource is an invaluable
tool for exam preparation and clinical competence.
Keywords:
NR 547, Advanced Pharmacology, Practice Exam, Pharmacotherapeutics, Drug Interactions, Nursing Education,
Exam Prep, 2026-2027
Answer Format:
Each question is followed by four answer choices, with the correct answer clearly indicated. A detailed rationale
explains why the correct answer is right and why the distractors are incorrect, referencing current guidelines and
pharmacological principles. This format reinforces learning and helps students identify common misconceptions.
Compliance Checklist:
Aligned with NR 547 course objectives
Based on latest 2026-2027 clinical guidelines
Page 1
, Includes rationales for all answers
Verified for accuracy by subject matter experts
Suitable for self-assessment and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, Distribution, Metabolism, 20%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Drug Classifications and 41-80 Antibiotics, Cardiovascular Agents, CNS 20%
Mechanisms Drugs, Endocrine Agents, Analgesics
Special Populations 81-110 Pediatrics, Geriatrics, Pregnancy/Lactation, 15%
Renal/Hepatic Impairment
Adverse Effects and Interactions 111-140 Side Effects, Drug-Drug Interactions, 15%
Contraindications, Toxicity Management
Clinical Decision-Making 141-170 Prescribing, Monitoring, Patient Education, 15%
Evidence-Based Practice
Case-Based Scenarios 171-200 Integrated Cases, Prioritization, Critical 15%
Thinking, Application
Page 2
,Q1. A patient with chronic kidney disease (eGFR 25 mL/min) and type 2 diabetes is
prescribed metformin. Which pharmacokinetic principle most directly explains the
increased risk of lactic acidosis in this patient?
A. Decreased first-pass metabolism leading to higher bioavailability
B. Reduced renal clearance causing drug accumulation
C. Increased volume of distribution due to edema
D. Altered protein binding increasing free drug fraction
Correct Answer: B. Reduced renal clearance causing drug accumulation
Rationale: Metformin is primarily excreted unchanged by the kidneys. In chronic kidney
disease, reduced renal clearance leads to drug accumulation, increasing the risk of lactic
acidosis. The other options are less directly related to metformin's pharmacokinetic
profile.
Why Wrong:
A - Metformin undergoes minimal first-pass metabolism; this is not the primary
mechanism.
C - Volume of distribution changes are not the main cause of metformin-induced lactic
acidosis in renal impairment.
D - Metformin is not highly protein-bound; altered protein binding is not a significant
factor.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 47
Q2. A patient on warfarin is started on rifampin for tuberculosis. Which
pharmacodynamic interaction is expected, and what monitoring adjustment is
required?
A. Increased warfarin effect; reduce warfarin dose
B. Decreased warfarin effect; increase warfarin dose
C. No interaction; monitor INR routinely
D. Increased bleeding risk; hold warfarin
Correct Answer: B. Decreased warfarin effect; increase warfarin dose
Rationale: Rifampin is a potent CYP450 enzyme inducer, particularly CYP2C9, which
metabolizes warfarin. This increases warfarin metabolism, decreasing its anticoagulant
effect, so the warfarin dose must be increased to maintain therapeutic INR.
Why Wrong:
A - Rifampin induces metabolism, not inhibits, so warfarin effect is decreased, not
increased.
C - A significant interaction exists; INR must be monitored more frequently and dose
adjusted.
D - Bleeding risk is decreased, not increased, due to reduced warfarin activity.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q3. A patient with major depressive disorder is prescribed phenelzine. Which dietary
restriction is critical to prevent a hypertensive crisis, and what is the mechanism?
A. Avoid tyramine-rich foods; MAO-A inhibition prevents tyramine metabolism
B. Avoid foods high in potassium; MAO-A inhibition alters electrolyte balance
C. Avoid caffeine; MAO-A inhibition potentiates stimulant effects
D. Avoid foods high in sodium; MAO-A inhibition causes fluid retention
Correct Answer: A. Avoid tyramine-rich foods; MAO-A inhibition prevents tyramine
metabolism
Rationale: Phenelzine is a nonselective MAO inhibitor. It blocks MAO-A in the gut,
preventing the breakdown of tyramine, leading to accumulation and release of
norepinephrine, causing hypertensive crisis. Tyramine-rich foods (aged cheese, cured
meats) must be avoided.
Why Wrong:
B - Potassium is not directly affected by MAO inhibition; this is not a dietary
restriction.
C - Caffeine is not specifically restricted with MAO inhibitors; tyramine is the main
concern.
D - Sodium restriction is not required; the interaction is with tyramine, not sodium.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29
Q4. Which drug is most likely to cause QT prolongation, and what electrolyte
imbalance exacerbates this risk?
A. Amiodarone; hypokalemia
B. Metformin; hyperkalemia
C. Lisinopril; hypocalcemia
D. Atorvastatin; hypermagnesemia
Correct Answer: A. Amiodarone; hypokalemia
Rationale: Amiodarone is a class III antiarrhythmic known to prolong the QT interval.
Hypokalemia (and hypomagnesemia) increases the risk of torsades de pointes by altering
cardiac repolarization. The other drugs are not associated with QT prolongation.
Why Wrong:
B - Metformin does not prolong QT and hyperkalemia is not an exacerbating factor.
C - Lisinopril does not prolong QT; hypocalcemia is not the primary electrolyte
concern.
D - Atorvastatin does not prolong QT; hypermagnesemia is not a risk factor.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 50
Page 4
